210 related articles for article (PubMed ID: 31142735)
1. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.
Hung MH; Chen YL; Chen LJ; Chu PY; Hsieh FS; Tsai MH; Shih CT; Chao TI; Huang CY; Chen KF
Cell Death Dis; 2019 May; 10(6):420. PubMed ID: 31142735
[TBL] [Abstract][Full Text] [Related]
2. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
[TBL] [Abstract][Full Text] [Related]
3. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
4. Zanthoxylum avicennae extract enhances GSK-3β to attenuate β-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice.
Wu HC; Lay IS; Shibu MA; Ho TJ; Cheng SM; Lin CH; Dung TD; Jeng LB; Viswanadha VP; Huang CY
Environ Toxicol; 2017 Sep; 32(9):2133-2143. PubMed ID: 28548306
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
6. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma.
Tan HY; Wang N; Li S; Hong M; Guo W; Man K; Cheng CS; Chen Z; Feng Y
Cell Physiol Biochem; 2018; 47(5):1819-1834. PubMed ID: 29953980
[TBL] [Abstract][Full Text] [Related]
7. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
12. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
Quan H; Li B; Yang J
Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
[TBL] [Abstract][Full Text] [Related]
14. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
[TBL] [Abstract][Full Text] [Related]
15. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists.
Yuan J; Han B; Hu H; Qian Y; Liu Z; Wei Z; Liang X; Jiang B; Shao C; Gong Y
J Pathol; 2015 Apr; 235(5):784-95. PubMed ID: 25430888
[TBL] [Abstract][Full Text] [Related]
16. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
17. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
18. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
19. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
[TBL] [Abstract][Full Text] [Related]
20. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
Zhang N; Chen X
Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
